ArticleJournal of pharmacokinetics and pharmacodynamics2006
Model-based drug development: the road to quantitative pharmacology.
Article in Journal of pharmacokinetics and pharmacodynamics, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
41 citing papers in PubMed.
- Dose/Exposure-Response Modeling to Support Dosing Recommendation for Phase III Development of Baricitinib in Patients with Rheumatoid Arthritis.CPT: pharmacometrics & systems pharmacology · 2017Trial
- Model Informed Pediatric Development Applied to Bilastine: Ontogenic PK Model Development, Dose Selection for First Time in Children and PK Study Design.Pharmaceutical research · 2017Trial
- Models for change in tumour size, appearance of new lesions and survival probability in patients with advanced epithelial ovarian cancer.British journal of clinical pharmacology · 2016Trial
- Exposure-response model for sibutramine and placebo: suggestion for application to long-term weight-control drug development.Drug design, development and therapy · 2015Trial
- Quantitative pharmacology approach in Alzheimer's disease: efficacy modeling of early clinical data to predict clinical outcome of tesofensine.The AAPS journal · 2010Trial
- Machine Learning-Augmented Precision Dosing: Integrating Pharmacokinetic Modeling With Clinical Decision Support.CPT: pharmacometrics & systems pharmacology · 2026Review
- Predicting tumor dynamics in treated patients from patient-derived-xenograft mouse models: a translational model-based approach.Journal of pharmacokinetics and pharmacodynamics · 2025Article
- Using mathematical modeling to estimate time-independent cancer chemotherapy efficacy parameters.In silico pharmacology · 2022Article
- Pharmacometrics meets statistics-A synergy for modern drug development.CPT: pharmacometrics & systems pharmacology · 2021Article
- Physiologically-Based Pharmacokinetic/Pharmacodynamic Model of MBQ-167 to Predict Tumor Growth Inhibition in Mice.Pharmaceutics · 2020Article
- Pharmacokinetics of gemcitabine and its amino acid ester prodrug following intravenous and oral administrations in mice.Biochemical pharmacology · 2020Article
- Mechanistic Multiscale Pharmacokinetic Model for the Anticancer Drug 2',2'-difluorodeoxycytidine (Gemcitabine) in Pancreatic Cancer.Clinical and translational science · 2020Article
- Translational Framework Predicting Tumour Response in Gemcitabine-Treated Patients with Advanced Pancreatic and Ovarian Cancer from Xenograft Studies.The AAPS journal · 2019Article
- Physiologically-based pharmacokinetic and pharmacodynamic models for gemcitabine and birinapant in pancreatic cancer xenografts.Journal of pharmacokinetics and pharmacodynamics · 2018Article
- Getting Innovative Therapies Faster to Patients at the Right Dose: Impact of Quantitative Pharmacology Towards First Registration and Expanding Therapeutic Use.Clinical pharmacology and therapeutics · 2018Article
- Challenges in translational drug research in neuropathic and inflammatory pain: the prerequisites for a new paradigm.European journal of clinical pharmacology · 2017Review
- Infliximab Dosing Strategies and Predicted Trough Exposure in Children With Crohn Disease.Journal of pediatric gastroenterology and nutrition · 2016Article
- Mechanism-based mathematical modeling of combined gemcitabine and birinapant in pancreatic cancer cells.Journal of pharmacokinetics and pharmacodynamics · 2015Article
- OARSI Clinical Trials Recommendations: Soluble biomarker assessments in clinical trials in osteoarthritis.Osteoarthritis and cartilage · 2015Review
- Pharmacologic considerations in use and development of antituberculosis drugs.Cold Spring Harbor perspectives in medicine · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
High development costs and low success rates in bringing new medicines to the market demand more efficient and effective approaches. Identified by the FDA as a valuable prognostic tool for fulfilling such a demand, model-based drug development is a mathematical and statistical approach that constructs, validates, and utilizes disease models, drug exposure-response models, and pharmacometric models to facilitate drug development. Quantitative pharmacology is a discipline that learns and confirms the key characteristics of new molecular entities in a quantitative manner, with goal of providing explicit, reproducible, and predictive evidence for optimizing drug development plans and enabling critical decision making. Model-based drug development serves as an integral part of quantitative pharmacology. This work reviews the general concept, basic elements, and evolving role of model-based drug development in quantitative pharmacology. Two case studies are presented to illustrate how the model-based drug development approach can facilitate knowledge management and decision making during drug development. The case studies also highlight the organizational learning that comes through implementation of quantitative pharmacology as a discipline. Finally, the prospects of quantitative pharmacology as an emerging discipline are discussed. Advances in this discipline will require continued collaboration between academia, industry and regulatory agencies.
Indexed as
Identifiers
16770528What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.